BionTech Covid-19 Vaccine | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
May 10, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, MAY 10, 2025

BionTech Covid-19 Vaccine

A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
Coronavirus chronicle

Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children

More than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy

A patient receives their coronavirus disease (COVID-19) vaccine booster during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, U.S., September 29, 2021. REUTERS/Emily Elconin/File Photo
Coronavirus chronicle

Pfizer/BioNTech Covid-19 vaccine effectiveness drops after 6 months, study shows

Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

US FDA grants full approval to Pfizer-BioNTech Covid-19 vaccine

Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

Pfizer, BioNtech submit data to FDA for Covid-19 vaccine booster authorisation

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

BioNTech says vaccine repeats beat devising new one for now

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

BioNTech Covid-19 vaccines coming to Taiwan, Chinese agent says

Syringes with the Pfizer-BioNTech vaccines to be administered against the coronavirus disease (COVID-19) lie on a tray during a program without an appointment in Sant Vicenc de Casteller, north of Barcelona, Spain, July 6, 2021. REUTERS/ Albert Gea
Coronavirus chronicle

TSMC says it is in the process of signing a deal for BioNTech Covid-19 vaccines

Taiwan Health Minister Chen Shih-chung holds a news conference about Taiwan's efforts to get into the World Health Organization in Taipei, Taiwan, May 15, 2020. REUTERS/Ann Wang
South Asia

Taiwan says request to drop word 'country' preceded BioNTech vaccine deal collapse

Ugur Sahin, CEO and co-founder of German biotech firm BioNTech. Picture: Reuters
Coronavirus chronicle

BioNTech says vaccine likely to be effective against India variant

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

BioNTech committed to deliver 1.8 bln doses of Covid-19 vaccine this year

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

Fosun Pharma's subsidiary, BioNTech to set up JV for Covid-19 vaccine production

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

BioNTech nearing request for approval of longer-lasting version of Covid vaccine

Ugur Sahin, CEO and co-founder of German biotech firm BioNTech. Picture: Reuters
Coronavirus chronicle

BioNTech CEO sees China approval for Covid shot by July

  • Show More
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net